Target
NKp46
4 abstracts
Abstract
A phase 1/2, open-label, multicenter trial investigating the safety, tolerability, and preliminary antineoplastic activity of IPH6501, a first-in-class NK cell engager, in patients with relapsed and/or refractory CD20-expressing non-Hodgkin lymphoma.Org: Peninsula Health, Peninsula Private Hospital,
Abstract
Interim analysis of a phase I study using cryopreserved non-genetically modified allogeneic natural killer cells with enhanced cytotoxicity (SNK02) in patients with advanced solid tumors without lymphodepletion.Org: Medical Imaging Center of Southern California, NKGen Biotech Inc.,
Abstract
A first-in-human study of CD123 NK cell engager SAR443579 in relapsed or refractory acute myeloid leukemia, B-cell acute lymphoblastic leukemia, or high-risk myelodysplasia.Org: City of Hope National Medical Center, Erasmus University Medical Center, Institut Paoli-Calmettes, Marseille, France, University Medical Center Groningen, MD Anderson Cancer Center,